Lysozyme fusion proteins in infections
US5993809A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Nov 18, 1998 |
| Grant date | Nov 30, 1999 |
| Priority date | — |
| Expiry date | Nov 18, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P31/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and composition for prophylaxis and/or treatment of bacterial infections, particularly bacterial respiratory infections. A fusion protein of lysozyme and the carboxyl terminal propeptide of surfactant protein-B (SP-B) with the preceding ten amino acids of the mature SP-B peptide is administered in a pharmaceutically acceptable medium to an individual. The fusion protein may be selected so as to deliver it to a target infection site, such as the lungs or gastrointestinal tract. The method and composition eliminates problems associated with conventional antibiotic treatments, such as inefficacy and promotion of antibiotic resistant bacterial strains.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.